Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
melanoma
Biotech
Pfizer offloads scrapped Seagen ADC to Medicus Pharma
Medicus paying $12 million upfront for rights to PF-08046031, which is designed to attack a cancer target called melanotransferrin or CD228.
Darren Incorvaia
Sep 3, 2026 11:31am
Merck-Moderna vaccine data spur talk of Keytruda-like impact
Aug 20, 2026 9:25am
Merck-Moderna cancer vax slows recurrence in ph. 3 trial
Aug 19, 2026 6:45am
Labcorp nabs FDA green light for BRAF melanoma diagnostic
Aug 10, 2026 9:28am
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
Jul 30, 2026 6:20pm
Regeneron rocked by failure as melonama drug can't beat Keytruda
May 18, 2026 4:40am
